Zai Lab Ltd., a Chinese drug developer working on cancer treatments, has picked banks to arrange a planned U.S. initial public offering that could raise about $150 million, people with knowledge of the matter said.
Continue reading this story with a subscription to DealStreetAsia.
Unlock your competitive advantage in a rapidly evolving scape. Our packages come with exclusive access to archives, content, data, discount on summit tickets & more. Be a part of our growing community now.